Thrombin generation as an acute effect of cigarette smoking.
The effects of acute smoking on hemostatic functions were investigated in healthy young volunteers. Immediately after the volunteers smoked, a significant increase in blood pressure and heart rate was accompanied by a rise in plasma epinephrine. Fibrinopeptide A and thrombin-antithrombin III complex as markers of thrombin generation in vivo were significantly increased after smoking. The increase in thrombin-antithrombin III complex was significantly correlated with that of plasma epinephrine. Both antigen and activity of tissue plasminogen activator and plasmin-inhibitor complex as markers of fibrinolytic activity in vivo were markedly increased after smoking, whereas D-dimer, plasminogen activator inhibitor antigen, fibrinogen, and both beta-thromboglobulin and platelet factor 4 as markers of platelet activation in vivo were not changed. No effects were observed after sham smoking under exactly identical conditions in the same subjects. Thus thrombin generation was observed as acute hemostatic effects of smoking. Enhanced fibrinolytic response may counteract an increased procoagulant activity. Patients with vascular disease might be more susceptible to a state of disequilibrium in favor of coagulation, which may partly explain a mechanism by which cigarette smoking leads to cardiovascular morbidity and mortality.
Department of Cardiology, Jichi Medical School, Japan.
S
S
Kimura
M
M
Nishinaga
T
T
Ozawa
K
K
Shimada
D000328:Adult; D000933:Antifibrinolytic Agents; D000990:Antithrombin III / Q000032:analysis; D001777:Blood Coagulation / Q000502:physiology; D001794:Blood Pressure / Q000502:physiology; D004837:Epinephrine / Q000097:blood; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D005341:Fibrinolysin; D005342:Fibrinolysis / Q000502:physiology; D005344:Fibrinopeptide A / Q000032:analysis; D006339:Heart Rate / Q000502:physiology; D006487:Hemostasis / Q000502:physiology; D006801:Humans; D008297:Male; D009638:Norepinephrine / Q000097:blood; D010447:Peptide Hydrolases / Q000032:analysis; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D015539:Platelet Activation / Q000502:physiology; D010978:Platelet Factor 4 / Q000032:analysis; D012907:Smoking / Q000097:blood* / Q000503:physiopathology; D013917:Thrombin / Q000096:biosynthesis*; D010959:Tissue Plasminogen Activator / Q000097:blood; D001620:beta-Thromboglobulin / Q000032:analysis
D000933:Antifibrinolytic Agents; D005338:Fibrin Fibrinogen Degradation Products; D017395:Plasminogen Activator Inhibitor 1; C046193:antithrombin III-protease complex; D001620:beta-Thromboglobulin; C036309:fibrin fragment D; D005344:Fibrinopeptide A; D010978:Platelet Factor 4; D000990:Antithrombin III; D005340:Fibrinogen; D010447:Peptide Hydrolases; D013917:Thrombin; D010959:Tissue Plasminogen Activator; D005341:Fibrinolysin; D009638:Norepinephrine; D004837:Epinephrine